Mediaspace scheduled maintenance: Aug 25, 2026 07:00 - 12:00 AM. During this time, videos will be temporarily unavailable. Check status updates.

Home

Person

Nicolo Rigamonti

This person has left EPFL

About
Privacy
Disclaimer

Graph Chatbot

Related publications (4)

Please note that this is not a complete list of this person’s publications. It includes only semantically relevant works. For a full list, please refer to Infoscience.

About this result

This page is automatically generated and may contain information that is not correct, complete, up-to-date, or relevant to your search query. The same applies to every other page on this website. Please make sure to verify the information with EPFL's official sources.

Related publications (4)

Please note that this is not a complete list of this person’s publications. It includes only semantically relevant works. For a full list, please refer to Infoscience.

Dual angiopoietin-2 and VEGFA inhibition elicits antitumor immunity that is enhanced by PD-1 checkpoint blockade

Michele De Palma, Ece Kadioglu, Nicolo Rigamonti, Damya Laoui, Céline Wyser Rmili

Pathological angiogenesis is a hallmark of cancer and a therapeutic target. Vascular endothelial growth factor A (VEGFA) and angiopoietin-2 (ANGPT2; also known as ANG2) are proangiogenic cytokines that sustain tumor angiogenesis and limit antitumor immunit ...

American Association for the Advancement of Science2017

Role of angiopoietin-2 in adaptive tumor resistance to VEGF signaling blockade

Michele De Palma, Ece Kadioglu, Ioanna Keklikoglou, Nicolo Rigamonti, Céline Wyser Rmili

Angiopoietin-2 (ANG2/ANGPT2) is a context-dependent TIE2 receptor agonist/antagonist and proangiogenic factor. Although ANG2 neutralization improves tumor angiogenesis and growth inhibition by vascular endothelial growth factor (VEGF)-A signaling blockade, ...

Elsevier2014

Optimized antiangiogenic reprogramming of the tumor microenvironment potentiates CD40 immunotherapy

Daniela Pais Ferreira, Martina Stephanie Anne Schmittnägel, Michele De Palma, Alan Nicolas Thierry Guichard, Nicolo Rigamonti

Cancer immunotherapies are increasingly combined with targeted therapies to improve therapeutic outcomes. We show that combination of agonistic anti-CD40 with antiangiogenic antibodies targeting 2 proangiogenic factors, vascular endothelial growth factor A ...

2020